AI-generated analysis. Always verify with the original filing.
Aspire Biopharma Holdings, Inc. entered into a Securities Purchase Agreement for a private placement of Series A Convertible Preferred Stock, raising $11 million in gross proceeds at the initial closing and potentially up to $21 million in total. Concurrently, Donald G. Fell resigned from the Board and Philip Balatsos was appointed as a director.
Event Type
Disclosure
Mandatory
Variant
8-K
. Entry into a Material Definitive Agreement. Securities Purchase Agreement On February 6, 2026, Aspire Biopharma Holdings, Inc. (the “ Company ”) entered into
. The Preferred Stock is being sold and, upon conversion the securities underlying the Preferred Stock, will be issued without registration under the Securities
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain; Compensatory Arrangements of Certain Officers. On February 6, 2026, D
(including Exhibit 99.1 hereto), is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to
Financial Statements and Exhibits. Exhibit Number Description 10.1 Form of Securities Purchase Agreement, dated February 6, 2026 by and among Aspire Biopharma H
Donald G. Fell
Effective: 2026-02-06
Not due to any disagreement with the Company.
Philip Balatsos
Effective: 2026-02-06
To fill a vacancy on the Board of Directors.
Material Agreement